logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 

Equities – Your destination to connect with the growth investment community.

Incyte Corporation Skyrockets on Promising Trial for Jakafi

  +Follow August 21, 2013 9:20AM
Share:
Tickers Mentioned:

Pharmaceutical company Incyte Corporation (INCY) released very positive news on Aug. 21, revealing that their pancreatic cancer treatment drug ruxolitinib, marketed under the trade name Jakafi, had performed very well in Phase II trials, and that the drug could now move on to Phase III.

Incyte Executive Vice President Richard S. Levy pointed out that sufferers from advanced pancreatic cancer currently have very few options. If approved, the orally-administered drug would be one of the first on the market that exists as "an attractive treatment option" for sufferers of pancreatic cancer.

If approved by the FDA, this would be a major breakthrough. Metastatic pancreatic cancer has the lowest survival rate of any form of cancer. Currently, less than one percent of people afflicted survive more than five years.

Jakafi's ability to increase lifespan for sufferers looks very promising. In the Phase II trials, the six month survival rate for patients (when coupled with chemotherapy treatment) for Jakafi was 42 percent, compared to 11 percent for patients on a placebo.

Jakafi was first approved by the Food and Drug Administration in 2011 to treat a bone marrow disease. After its success in that arena, the company specualted that the drug might effectively treat other types of cancer as well. Now, the drug is fast aproaching approval to treat pancreatic cancer as well. Though it is currently the only drug the company has gotten passed by the USFDA. Jakafi seems to be fulfilling early analyst speculation that it could be a billion dollar blockbuster drug for the Delaware-based drug maker.

Incyte earned $54.1 million from sales of Jakafi in the second quarter of 2013, and expects to earn between $220 and $230 million total this year.

Incyte rocketed on the news, and went up 29.19 percent to hit $34.88 a share. They’re up 58.82 percent on the year.

(image courtesy of Wikimedia commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for INCY
Helen Ong
3 May 15 10:53:09
RT @TomSilver39: Nomura" $GILD Harvoni Beats; HIV Impacted by Inventory Drawdown,Increasingly open to M&A=fit M&A criteria include $INCY, $…
Michael
3 May 15 10:38:34
@TomSilver39 I like $INCY. Best Onc Pipeline that's close to release. Is GS still waiting for "significant discounts" to Harvoni?
Luis Gutierrez
3 May 15 10:34:34
RT @TomSilver39: Nomura" $GILD Harvoni Beats; HIV Impacted by Inventory Drawdown,Increasingly open to M&A=fit M&A criteria include $INCY, $…
Eternity101
3 May 15 09:50:07
RT @TomSilver39: Nomura" $GILD Harvoni Beats; HIV Impacted by Inventory Drawdown,Increasingly open to M&A=fit M&A criteria include $INCY, $…
Tom Silver
3 May 15 09:49:47
Nomura" $GILD Harvoni Beats; HIV Impacted by Inventory Drawdown,Increasingly open to M&A=fit M&A criteria include $INCY, $ICPT and $RCPT."
ProTradersNews
3 May 15 08:22:04
$INCY: Incyte Earns Overweight Rating from Piper Jaffray (INCY): http://t.co/gqamA18V2l
Sleek Money
3 May 15 08:20:29
Incyte Earns Overweight Rating from Piper Jaffray $INCY http://t.co/X5ZxryEhLx
PennyStock Zone
3 May 15 07:37:06
Tip #4 How to identify a HOT trading SECTOR? http://t.co/WvpU6esv0n $MZOR $PNC $LBTYA $JOY $QTWO $TRN $ACXM $INCY
crassus
3 May 15 07:17:20
Interesting bios work in progress http://t.co/B07FxSb1PJ $INCY $PCYC $SGEN $EBIO $EXEL $KYTH $CYTK
Kristina Duering
3 May 15 06:55:06
RT @crusadernz: BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.c…
Kristina Duering
3 May 15 05:18:53
@BiotechBaller @Gupta_Calling My core stocks are $INCY $FMI $SGEN $SAGE $IMGN $ARRY $BBAGF $ESPR $GNFTF $CLVS $ADRO $RDUS $KPTI
Capital Market Labs
2 May 15 23:55:19
$BMRN vs. $INCY vs. $ALKS vs. $PCYC Compared Across 9 Critical Measures http://t.co/fPh86FIQ5r http://t.co/FN9pV7X8W0
PennyStock Zone
2 May 15 22:12:09
Tip #4 How to identify a HOT trading SECTOR? http://t.co/WvpU6eK6oX $MZOR $PNC $LBTYA $JOY $QTWO $TRN $ACXM $INCY
Ponty
2 May 15 18:51:04
RT @w_biltmore85: @CRAZYDOGANDFATC @MomoTrades15 @unifygovernment @pbmech @skaushi @rajramaswamy not to mention $incy is baker brothers lar…
Joe W.
2 May 15 18:33:00
@CRAZYDOGANDFATC @MomoTrades15 @unifygovernment @pbmech @skaushi @rajramaswamy not to mention $incy is baker brothers largest position also
Joe W.
2 May 15 18:28:32
@DrPaulyDeSantis @WilliamGerber1 @adamfeuerstein that's right, might get something on their cc this week $incy
WKRB News
2 May 15 16:35:16
Incyte Rating Reiterated by Piper Jaffray $INCY http://t.co/816cy4sMen
Breaking News Now
2 May 15 16:32:02
$INCY: Incyte's "Overweight" Rating Reaffirmed at Piper Jaffray (INCY): http://t.co/dRWNTKCCZE
Bio Stocks™
2 May 15 16:11:46
RT @crusadernz: BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.c…
Don H
2 May 15 15:30:09
RT @crusadernz: BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.c…
PennyStock Zone
2 May 15 15:26:22
Tip #4 How to identify a HOT trading SECTOR? http://t.co/WvpU6esv0n $MZOR $PNC $LBTYA $JOY $QTWO $TRN $ACXM $INCY
Gotham City Capital
2 May 15 15:16:58
RT @crusadernz: BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.c…
BioPharmCatalyst
2 May 15 15:12:31
BioPharmCatalyst updates: $INCY $SGEN $BMRN $CEMP $CYTK CYTR $EBIO $EXEL $LXRX $MDCO $NBIX THLD THRX TSRO + more http://t.co/ZzM188O5e5
Joe W.
2 May 15 13:09:39
@MomoTrades15 @unifygovernment @pbmech @skaushi @rajramaswamy Yeah I got back in $INCY $96 this week, they should blow it out at ASCO again
The Legacy News
2 May 15 12:42:15
Brean Capital Boosts Incyte Price Target to $107.00 $INCY http://t.co/zPh1eY76ui
Sleek Money
2 May 15 12:35:19
Incyte PT Raised to $107.00 at Brean Capital $INCY http://t.co/LBo1IwdkgB
ProVesting
2 May 15 12:32:04
$INCY: Incyte PT Raised to $107.00 at Brean Capital (INCY): http://t.co/zhQu3GLB5p
ProVesting
2 May 15 12:32:03
$INCY: Incyte Given New $107.00 Price Target at Brean Capital (INCY): http://t.co/GDSXwbJmNk
US Banking News
2 May 15 04:31:42
Incyte Earns Overweight Rating from Piper Jaffray $INCY http://t.co/MEaA0PtEE7
Capital Market Labs
2 May 15 02:38:34
$INCY vs. $PCYC vs. $BMRN vs. $MDVN Compared Across 9 Critical Measures http://t.co/afD4XRxSWO http://t.co/bwLH0urpPt
Capital Market Labs
2 May 15 01:11:30
$INCY vs. $PCYC vs. $ISIS vs. $BMRN Compared Across 9 Critical Measures http://t.co/QtPpbwabHZ http://t.co/OUSCDJsvC9
Capital Market Labs
2 May 15 00:47:44
$VRTX vs. $ALXN vs. $PCYC vs. $INCY Compared Across 9 Critical Measures http://t.co/Gd5xD2XeAx http://t.co/W0Az80obh2
Joe W.
1 May 15 19:33:44
@MomoTrades15 @pbmech @skaushi @rajramaswamy Love me some $ESPR, think $INCY is going to really start pushing higher
The Legacy News
1 May 15 18:27:21
Piper Jaffray Reaffirms “Overweight” Rating for Incyte $INCY http://t.co/MZhMspEiHq
US Consumer News
1 May 15 18:17:25
Incyte's overweight rating reiterated at Piper Jaffray. $121.00 PT. http://t.co/fF90X0a1jP $INCY #INCY
Analyst Ratings
1 May 15 18:17:21
Incyte's overweight rating reiterated at Piper Jaffray. $121.00 PT. http://t.co/iX3sT2hGFf $INCY #INCY
SwingTradeBot
1 May 15 14:35:22
Scan results - 1,2,3 Pullback Bullish today: $CAMP $GTLS $FRPT $RES $SOHU $INCY $AEC $DXCM $EDU $AMZN ... http://t.co/VO0eca5qw9
Erik Neelsen
1 May 15 14:11:46
RT @bstriz: $AGEN down ~5% from last week close, compare with $IBB $XBI $LCINDX all down > 10% on week. $AGEN up over 100% end 2014 pre $I…
Joe W.
1 May 15 13:30:55
$BMRN $INCY $CLDX $BLUE Cowen most loved https://t.co/Rq8KbHdKHu
biotechnology smith
1 May 15 12:06:14
$INCY - 3 Growth Stocks Near 52-Week Highs Worth Selling http://t.co/0BlXw0msBS
Rachel Smith
1 May 15 12:06:12
$INCY - 3 Growth Stocks Near 52-Week Highs Worth Selling http://t.co/LkDzCWDjIY
WKRB News
1 May 15 11:38:23
Incyte $INCY Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS http://t.co/wD7DQNLqLp
Lu
1 May 15 09:44:19
RT @AndyBiotech: Cowen May Biotech Thermometer Most Loved: $ALNY? $BLUE $BMRN $CLDX $INCY Most Hated: $AKAO $KERX $IMGN $SRPT $XNPT http…
Brian Strizich
1 May 15 08:32:43
$AGEN down ~5% from last week close, compare with $IBB $XBI $LCINDX all down > 10% on week. $AGEN up over 100% end 2014 pre $INCY deal
Capital Market Labs
1 May 15 08:09:26
$INCY Assets are Growing. #CML_INCY #CML_Assets http://t.co/xXxPOT9CeK http://t.co/W3LWbLQ0OT
dougheuring
1 May 15 08:06:58
RT @AndyBiotech: Cowen May Biotech Thermometer Most Loved: $ALNY? $BLUE $BMRN $CLDX $INCY Most Hated: $AKAO $KERX $IMGN $SRPT $XNPT http…
Christine Folgmann
1 May 15 08:04:35
RT @BioInvestor2013: @BioInvestor2013 $BLRX BL-8040 positive data Whispers http://t.co/LPBsr7xUwR … … … $AAVI $DVAX $INCY $GILD $IS…
Don H
1 May 15 07:57:19
RT @AndyBiotech: Cowen May Biotech Thermometer Most Loved: $ALNY? $BLUE $BMRN $CLDX $INCY Most Hated: $AKAO $KERX $IMGN $SRPT $XNPT http…
23aloha
1 May 15 07:57:12
RT @AndyBiotech: Cowen May Biotech Thermometer Most Loved: $ALNY? $BLUE $BMRN $CLDX $INCY Most Hated: $AKAO $KERX $IMGN $SRPT $XNPT http…
Andy Biotech
1 May 15 07:57:01
Cowen May Biotech Thermometer Most Loved: $ALNY? $BLUE $BMRN $CLDX $INCY Most Hated: $AKAO $KERX $IMGN $SRPT $XNPT http://t.co/yP3K4Yajy6
				
				
  +Follow August 21, 2013 9:20AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN